Exiqon’s bottom line is red, but the company sticks with forecast
The first quarter interim report from the Danish gene analysis unit Exiqon shows a red bottom line, but the company maintains its positive expectations for the full year.
BY ELIZABETH MØNSTED JOHANSEN
In spite of a red bottom line, things are still looking solid for sales at the Danish gene analysis company Exiqon. This is evident from the company’s first quarter interim report, published this week. The company points to factors including the early Easter as reasons why the development in sales were less strong than expected.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Shareholder rebellion brewing at Exiqon
For abonnenter
Exiqon publishes new data for prostate cancer test
For abonnenter
